Exact Sciences stock holds steady as investors await next earnings signal
Published on 08/20/2026 at 17:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exact Sciences (US30063P1057) stock is trading steadily in August 2026 as investors weigh the company’s latest quarterly revenue trajectory and await updated guidance following results for the period ended June 30, 2026.
Recent earnings trends and revenue scale
Recent reporting for the quarter ended June 30, 2026 shows that Exact Sciences generated quarterly revenue in the hundreds of millions of dollars, underscoring the company’s position as a scaled player in cancer diagnostics and screening.
For context, the latest figures indicate that revenue in the most recent reported quarter was higher than in the same quarter a year earlier, marking year-over-year growth in the mid-single to double-digit percentage range and reflecting continued adoption of its core colorectal cancer screening tests.
Profitability, cash flow and guidance context
While Exact Sciences continues to invest in research, commercialization and international expansion, recent quarterly results show a clear focus on improving margins and cash flow compared with prior periods, even as the company balances growth spending with a path toward sustained profitability.
Management has indicated that current full-year guidance for 2026 assumes continued revenue growth from its flagship screening franchise along with ongoing operating cost discipline, which together are expected to narrow losses compared with the prior year.
Product spotlight: Cologuard colorectal cancer test
A central pillar of Exact Sciences business model is its noninvasive stool-based DNA test for colorectal cancer screening, marketed for use in average-risk adults as an at-home alternative to traditional colonoscopy. The product generates recurring testing volume as patients follow recommended multi-year screening intervals, and it provides physicians with a tool that can improve screening adherence and early cancer detection rates.
Exact Sciences stock on Nasdaq
Exact Sciences stock trades on the Nasdaq in US dollars, giving investors direct exposure to the company’s cancer diagnostics and screening growth story through a liquid US listing.
Fact box
Company: Exact Sciences Corp.
ISIN: US30063P1057
Ticker: EXAS
Exchange: Nasdaq
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq index universe
